Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty

NCT03169231 is registered in ClinicalTrials.gov with Longeveron Inc. as lead sponsor.

NCT NCT03169231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03169231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
Lead sponsor
Longeveron Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2017
Completion date
September 30, 2021
Enrollment
150 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

aging frailty